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INTRODUCTION
Any study exploring speciﬁc research
questions requires to test well-deﬁned
hypotheses that efﬁciently translate these
questions into measurable quantities. To
attribute differences in outcomes between
two or more groups to their respective
different exposure levels, the ﬂagship
comparative approach is the randomised
clinical trial (RCT).
An RCT is not always feasible, as is the
case if the exposure of interest cannot be
reasonably randomised, such as smoking,
age, family or personal history of a
disease. A cohort study is the next most
rigorous approach to answer cause and
effect questions, sharing with an RCT the
advantage of prospective follow-up. In
addition, observational studies are more
suitable to answer certain important ques-
tions for an intervention such as detecting
rare or late adverse effects of treatments.1
A comparative study that lacks the ran-
domisation component should not also
lag behind in other rigorous requirements
that are customarily expected of rando-
mised studies. The value of the scientiﬁc
evidence produced by an observational
study lies equally heavily on how explicit
its design characteristics are in the proto-
col, and how faithfully the study imple-
mentation followed the study protocol
design. Guidelines to that effect are avail-
able and should be respected.2
One of the most crucial parameters in a
study is the choice of the end point that
would best translate the objective and
capture the effect of interest. It is often
the case that several relevant end points
are of comparable importance and it
might be difﬁcult to select the most
appropriate one. In those situations, the
union of several end points, a composite
end point (CE), is used as the primary
end point (PE) of interest. A key advan-
tage of a CE is that it provides a better
description of a disease process.3 For
example, in the cardiovascular literature,
efﬁcacy of interventions is often expressed
as a composite of major cardiovascular
events (MACE). In the HORIZONS-AMI
clinical trial,4 two primary 30-day end
points were prespeciﬁed: major bleeding
and net adverse clinical events, a compos-
ite of major bleeding and MACE. In this
trial, MACE is composed of death, rein-
farction, target vessel revascularisation for
ischaemia and stroke. While major bleed-
ing is the relevant end point (RE), the CE
takes into account all other additional
adverse clinical events including death.
Several authors have discussed the
advantages and disadvantages of using a
CE from a clinical or statistical perspec-
tive.3 5–8 A CE could give an appropriate
reﬂection of the clinical spectrum of
important outcomes associated with the
disease. It avoids the need to choose a
single PE when many may be of equal
importance. A CE could avoid interpret-
ational problems associated with compet-
ing risks by preventing an apparent
beneﬁt being attributed to a given event
when in fact the beneﬁt appears to be due
to the increased occurrence of a more
serious outcome, such as death. Finally, a
CE can eliminate multiplicity problems
associated with comparing treatments for
several distinct end points. However, a
misleading impression of the beneﬁcial
effect of a treatment can occur for a CE
with component end points of highly dif-
fering clinical importance since the treat-
ment might only beneﬁt the less
important end points. Also, the lack of
treatment effect on the CE does not imply
that there is no treatment effect on some
of the components.9
Assume we have two possible end
points, labelled E1 and E2, of comparable
importance and could satisfactorily answer
the study’s primary clinical question.
Suppose that E2 is a secondary end point.
We refer to E1 as the RE and E2 as the
additional end point (AE), and each can
be a simple or CE. The CE, E*, is formally
deﬁned as the occurrence of either E1 or
E2, and for time-to-event end points,
time-to E* corresponds to the time for the
ﬁrst event of either E1 or E2 to occur.
At the planning phase of a cohort study,
the choice of the PE is of crucial import-
ance: sample size (SS) computations are
based on this PE and primary analyses
also focus on the PE. The more efﬁcient
PE is the one requiring a smaller SS for
the speciﬁed signiﬁcance level and power.
Under the premises of having to choose
between a relevant E1 and composite E*, a
measure quantifying which of the two end
points would be more efﬁcient is of great
help. Such a measure has been derived for
RCTs10 and is based on the evaluation of
the Asymptotic Relative Efﬁciency (ARE)
of the two end points.
The purpose of the present paper is to
show that the ARE method is a useful
tool to guide the choice of the most efﬁ-
cient end point. The methodology is
described for the design of observational
cohort studies and is particularly appeal-
ing to conﬁrm or refute previous ﬁndings,
framed in clearly deﬁned hypotheses
about the beneﬁt of an intervention.
THE ARE METHOD
The ARE method for RCTs
In an RCT, the research question of inter-
est is usually whether a new treatment has
higher efﬁcacy than the currently recom-
mended treatment. Consider a two-arm
randomised study with assignment to an
active or control treatment, for example,
new treatment versus standard of care.
Efﬁcacy is sometimes measured by a PE
expressed as time from randomisation to
the occurrence of an event. Assume that
we are establishing the treatment effect in
terms of the HR and that the difference
between treatment groups is tested by
means of a logrank test. Our dilemma is
whether to use E1 as PE or the CE E*.
Note that two different logrank tests
would be used for E1 and E*.
The ARE value between E* and E1 is a
measure of the relative power of the two
tests and can be interpreted as the ratio of
efﬁciencies using each outcome10 or the
ratio of required SSs to achieve a desired
power.11 ARE values larger than 1 indi-
cate that the CE E* is more efﬁcient,
leading to a design with a smaller SS than
E1 and it would be recommended as the
PE for the investigation.
The ARE method would not be of prac-
tical use if it could not be computed on
the basis of easily interpretable, intuitive
and plausible anticipated parameters. As
shown in Gómez and Lagakos, the ARE
value depends on the probability p1 and
p2 of observing the end points E1 and E2
in the control group during the follow-up
and the relative treatment effects on E1
and E2 given by the HRs HR1 and HR2.
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The ARE method further requires inde-
pendent censoring, the speciﬁcation of the
expected behaviour of the risk of develop-
ing E1 and E2 (decreasing, constant or
increasing over time) and the proportion
of individuals allocated to each treatment
group, all standard assumptions required
for the computation of the SS in a study.
The dependence between the times to E1
and to E2 is also needed. However, it has
been proven that different dependence
structures lead to similar results12 and dif-
ferent degrees of association, given by
Spearman’s r, yield, in many situations,
to similar recommendations on the
choice of the end point. A free web plat-
form CompARE (https://cinna.upc.edu/
compare) has been developed to choose
between E* and E1, based on the ARE
value, in the framework of an RCT.
The ARE method for observational
studies
Specifying the SS or the statistical power
to detect differences between groups,
during the design stage of an RCT, is
crucial for ﬁnancial and ethical reasons.
This also holds true for observational
studies, since a smaller SS implies shorter
recruitment periods, reducing the cost
and duration of a study. The STROBE
reporting guidelines requires reporting of
the key elements of study design and how
the study size was arrived at.2 Hence, the
choice of the PE is undoubtedly a corner-
stone, equally so in an RCT and in an
observational cohort study.
The ARE method for an RCT is based
on the logrank test, established to test the
efﬁcacy of a new treatment in comparison
with a control treatment for a time–
to-event end point. When comparing the
survival experience of two groups with
different baseline exposures in a cohort
observational study through the Cox
model,13 the logrank test could still be
used to compute the SS. However, it can
be proved that the power obtained on the
basis of the logrank test formula14 overes-
timates the true power of non-randomised
comparisons when the main exposure
(X1) and the covariates (X2,…,Xk) are
correlated. SS formulae for some special
cases in which X1 and X2,…,Xk are corre-
lated are provided.15 These formulae
essentially correspond to Schoenfeld’s
formula14 divided by 1–r2, that is, inﬂated
(in prospective studies) by the squared
multiple correlation coefﬁcient r2 of
regressing treatment X1 on the covariates
X2,…,Xk. While in an RCT the null
hypothesis of no treatment difference is
established as the equality of the two
hazard functions, in an observational
study, conceptualised as a conditionally
randomised experiment,16 the null
hypothesis would depend on the cov-
ariates. If a proportional hazards
model is assumed, then the hazard,
given a speciﬁc distribution of covari-
ates X=(x1,x2,…,xk), can be modelled
as h(t;X)=h0(t)exp(β1x1+ β2x2+…+ βkxk).
Consequently, the HR between
exposed (x1=1) and unexposed (x1=0) is
HR=exp(β1). The null and alternative
hypotheses would thus be respectively
stated as H0: (β1,β2,…, βk)=(0,β2,…, βk)
and H1: (β1,β2,…, βk)=(β*,β2,…, βk). In
this situation, power or SS calculations
might require additional considerations.17
As is often the case when computing the
SS in an observational study, the marginal
hazard functions replace the conditional
hazard for every set of covariates. The
‘crude’ null hypothesis is thus used
instead and, for every confounding covari-
ate, an increase in the SS of about 10% is
added.18 19 Taking this into account, the
ARE method is directly applicable to
observational studies.
The role that censoring could play with
respect to any combination of covariates
has to be taken into account as well.
Several approaches have been developed
to address these issues, such as the estima-
tion of the conditional probability of
being censored, given the individual’s cov-
ariates by the inverse probability weight-
ing method20 21 and the rank preserving
structural failure time models.22 When
applying the ARE method to an observa-
tional study, the same censoring
mechanism in the exposed and unexposed
groups, given a speciﬁc distribution of
covariates, is required (see online supple-
mentary ﬁles for more information). The
ARE method could accommodate differ-
ent censoring distributions; however, the
web platform CompARE is by now only
developed for administrative censoring.
Under these premises, and assuming
that the ARE value can be interpreted as a
ratio of needed SSs,11 an ARE value equal
to 1.2 would mean that E1 requires an SS,
which is 20% higher than for E*, to
achieve the same power.
APPLICATION OF THE ARE METHOD
The application of the ARE method to
observational cohort studies is illustrated
using the results of a cohort published
study as if they were the anticipated
values the investigators would have had
available when designing the study.
Alcántara et al23 recently aimed to study
the effect of concurrent depression and
stress in adults with coronary heart
disease on the risk of suffering myocardial
infarction (MI) or death. In a cohort of
4487 patients, 274 (6.1%) were exposed
to high stress and high depressive symp-
toms and 3613 (80.5%) to low stress and
low depressive symptoms. The remaining
600 individuals (13.4%), who were
exposed to high stress and low depressive
symptoms or vice versa, are not included
in this example. Among these 3887
patients followed for 2.5 years, 408
(10.5%) experienced the CE of either MI
or death. Speciﬁcally, 219 (5.6%) suffered
an event of MI and 279 (6.8%) died
during the follow-up.
The authors’ main analysis was based
on the results on the CE of MI or death.
After adjusting for several potential con-
founders, participants with concurrent
high stress and high depressive symptoms
had a 48% higher risk of experiencing the
CE compared to the unexposed group
(HR=1.48, 95% CI (1.08 to 2.02)).
Given the SS and characteristics of the
study population, and considering a level
of signiﬁcance of 5%, the power to
Figure 1 Screenshot from the free web platform CompARE (https://cinna.upc.edu/compare) with information from the relevant end point E1
(myocardial infarction) and additional end point E2 (all-cause death), its probabilities in the unexposed group (p1 and p2) and the relative treatment
effect on E1 given by HR1.
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consider this difference as statistically sig-
niﬁcant is 53%.14
In this study, the observed effect on the
CE of MI and death was found to be sig-
niﬁcant. Let us explore the result if the
initial plan of the authors would have
been to investigate the effect of concur-
rent stress and depression on either MI or
death alone. When using death as the
main end point, the results would have
been similar to the original ones. In fact,
the authors found that exposed indivi-
duals had a 52% higher risk of death
compared to those unexposed (HR=1.52,
95% CI (1.05 to 2.21)) and the corre-
sponding power is 42%. On the other
hand, the main ﬁnding of this study
would have been of no association when
considering MI alone. The authors found
that the exposed group had a 12% higher
risk of MI than the unexposed group
(HR=1.12, 95% CI (0.70 to 1.79)) and
the corresponding power is only 6%.
Using the ARE method, it is possible to
anticipate whether the addition of death
to MI would generally require a smaller
SS to detect a speciﬁc difference, com-
pared to considering MI alone or vice
versa. In other words, the ARE method
provides the outcome achieving a higher
power, assuming a given SS, and thus
allows to specify in advance which should
be the main outcome of the study.
We have used the CompARE platform
to illustrate these computations. To this
end, we provide the expected anticipated
risk for the RE (MI) of p1=5.5% and AE
(all-cause death) of p2=6.8% in the unex-
posed group during the follow-up time,
and the effect of the exposure on MI
(HR=1.12) (ﬁgure 1). We obtain a plot
for different correlations between MI and
all-cause death and for different HRs on
the all-cause death, illustrating different
potential effects of the exposure on all-
cause death (ﬁgure 2). The ARE method
shows that it would have been more efﬁ-
cient to consider MI alone (ARE≤1) if the
exposure would increase the death risk by
less than 5%, that is, HR≤1.05, while it
would have been more efﬁcient to con-
sider the CE of MI and death (ARE>1)
for an increase in risk death of more than
5%, that is, HR>1.05. Since in this study
the authors observed an increased death
risk of 52% in the exposed group com-
pared to the unexposed group, their
consideration of the CE as the PE was the
right decision, requiring a smaller SS than
MI alone.
Analogously, it is possible to explore
whether it is more efﬁcient to use death
alone or consider the CE of death or MI,
obtaining a plot for different HRs on MI
(ﬁgure 3). It would have been more efﬁ-
cient to consider death alone (ARE≤1)
whenever the exposure increases the risk
of MI by less than 20% (HR≤1.20).
DISCUSSION
The choice of the PE is crucial during the
design stage of any type of study. When
several potential end points are of
comparable importance to answer the
research question of interest, other factors
might be considered in order to choose
the most suitable one among them. The
ARE method provides a tool to make a
more informed choice of the PE, given a
small set of easily interpretable and antici-
pated parameters. This paper has shown
how to use the ARE method in the design
Figure 2 Asymptotic Relative Efﬁciency (ARE) of the composite end point E* (MI or all-cause
death) versus the relevant end point E1 (MI) for different values of Spearman’s correlation
coefﬁcient and different effects of the exposure on the additional end point E2 (all-cause death)
given by HR_AE. The plots correspond to: expected anticipated risk for MI in the unexposed
group during the follow-up time, p1=5.5%; expected anticipated risk for all-cause death in the
unexposed group during the follow-up time, p2=6.8%; effect of the exposure on MI,
HR_RE=1.12. MI, myocardial infarction; RE, relevant end point.
Figure 3 Asymptotic Relative Efﬁciency (ARE) of the composite end point E* (MI or all-cause
death) versus death for different values of Spearman’s correlation coefﬁcient and different effects
of the exposure on MI given by HR_AE. The plots correspond to: expected anticipated risk for MI
in the unexposed group during the follow-up time, p1=5.5%; expected anticipated risk for
all-cause death in the unexposed group during the follow-up time, p2=6.8%; effect of the
exposure on death, HR_RE=1.52. MI, myocardial infarction; RE, relevant end point.
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stage of an observational cohort study to
choose the end point requiring a smaller
study size. The CompARE platform could
be used to explore the relative efﬁciency
among multiple combinations of equally
aligned end points.
The application of the ARE method to
observational studies has limitations com-
pared to RCT. First, the loss of random-
isation makes the two treatment groups
unlikely to be exchangeable and leads to
the necessity to consider potential con-
founders. Second, the censoring mechan-
ism in the exposed and the unexposed
groups, given any combination of covari-
ates, plays an important role in the com-
putations of the ARE. Ideally, these
factors would have to be taken into
account when designing a study and we
are working in this direction.
Nevertheless, the most common approach
when computing the necessary SS is to
assume no confounding and therefore we
are not imposing new limitations on the
study design.
To summarise, researchers can use
CompARE for observational studies to
obtain plots, similar to the one repro-
duced in ﬁgure 2, to make a more
informed decision on the choice of the PE
in the study.
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